pacritinib

Ligand id: 7793

Name: pacritinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 68.74
Molecular weight 472.25
XLogP 4.52
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
International Nonproprietary Names
INN number INN
9385 pacritinib
Synonyms
SB-1518 | SB1518
Database Links
CAS Registry No. 937272-79-2
ChEMBL Ligand CHEMBL2035187
PubChem CID 46216796
Search Google for chemical match using the InChIKey HWXVIOGONBBTBY-ONEGZZNKSA-N
Search Google for chemicals with the same backbone HWXVIOGONBBTBY
Search PubMed clinical trials pacritinib
Search PubMed titles pacritinib
Search PubMed titles/abstracts pacritinib
Search UniChem for chemical match using the InChIKey HWXVIOGONBBTBY-ONEGZZNKSA-N
Search UniChem for chemicals with the same backbone HWXVIOGONBBTBY
Wikipedia Pacritinib
Comments
Pacritinib is an orally bioavailable and somewhat selective inhibitor of Janus kinase 2 (JAK2) and the JAK2 gain-of-function mutant JAK2V617F [2]. The compound is being tested for potential clinical antineoplastic activity.